Intellia Therapeutics Inc. (NASDAQ: NTLA) announced positive results from its phase 3 HAELO trial of lonvoguran ziclumeran for hereditary angioedema ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'April 27, 2026 10:48 AM